Erschienen in:
13.09.2019 | Scientific Letter
A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis
verfasst von:
Nagehan Aslan, Dincer Yildizdas, Yasemin Coban, Ozden Ozgur Horoz, Gulen Gul Mert, Neslihan Ozcan
Erschienen in:
Indian Journal of Pediatrics
|
Ausgabe 12/2019
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: Nusinersen (SPINRAZA-Biogen; Cambridge, MA, USA), is a new generation intrathecal treatment method for Spinal muscular atrophy (SMA) Type 1. This is an antisense oligonucleotide which produces effect by increasing SMN protein production [
1]. The effects and adverse effects of the drug have not been revealed completely [
2]. …